Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma

BACKGROUND: The optimal duration of immune checkpoint blockade (ICB) therapy is not well established. Active residual disease is considered prohibitive for treatment discontinuation and its detection by diagnostic CT imaging is limited. Here, we set out to determine the potential added value of 2-[1...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferdinandus, Justin, Zaremba, Anne, Zimmer, Lisa, Umutlu, Lale, Seifert, Robert, Barbato, Francesco, Ugurel, Selma, Chorti, Eleftheria, Grünwald, Viktor, Herrmann, Ken, Schadendorf, Dirk, Fendler, Wolfgang Peter, Livingstone, Elisabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8817553/
https://www.ncbi.nlm.nih.gov/pubmed/35123578
http://dx.doi.org/10.1186/s40644-022-00449-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8817553/
https://www.ncbi.nlm.nih.gov/pubmed/35123578
http://dx.doi.org/10.1186/s40644-022-00449-3

Ejemplares similares